Read More

Why Protalix BioTherapeutics Stock Is Soaring

Protalix BioTherapeutics Inc (AMEX:PLX) shares are surging Monday after the company said its Phase 3 trial for the treatment of Fabry disease met its primary endpoint. Fabry disease is an inherited disease resulting in progressive accumulation of abnormal deposits of a fatty substance in blood vessel walls throughout a person's body.

PLX